RESILIENCE helps you survive cancer with a strong heart

The Quest for an Early Marker of
Anthracycline-Induced Cardiotoxicity

There is a strong need to identify (bio)markers that can detect early stages of anthracycline-induced cardiotoxicity (AIC). In this editorial, 2 RESILIENCE researchers present the current state of the art of the field. They discuss data from al original paper published in the same issue of the journal by Bonny Ky´s team, showing that paraoxonase-1 (PON-1) appears a potential circulating biomarker of AIC in breat cancer patients. In this editorial, RESILIENCE project is presented as one of the most promising ongoing endeavors in the quest for the identification of sensitive markers of early AIC.

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions